Ipamorelin, GHRP-6 and GHRP-2 all act at the same receptor, and the interesting differences between them are in what else they do. All three are short synthetic peptides that engage the ghrelin receptor, and all three were developed before ghrelin itself was discovered. What separates them is selectivity: how much of the response they produce comes from the intended receptor and how much from elsewhere. That is the property the literature on ipamorelin is built around, and it is the reason the three are not interchangeable.
Three peptides, one receptor
| GHRP-6 | GHRP-2 | Ipamorelin | |
|---|---|---|---|
| Residues | 6 | 6 | 5 |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2 | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Introduced | 1980s | 1990s | 1998 |
| D-amino acids | 2 | 3 | 2 |
| Reported selectivity | Lowest of the three | Intermediate | Highest |
| Approx. mass | 873 Da | 818 Da | 712 Da |
Every one of them is built the same way: a handful of residues, several of them in the D configuration, a C-terminal amide, and a bulky aromatic side chain near the middle. The D-amino acids are there for stability, and the aromatic group is what the receptor recognises. The differences are in the details of which aromatic group and what sits at the N-terminus.
What does "selective" mean for a secretagogue?
That the compound produces the intended release without also producing the others that the receptor can trigger. Ghrelin receptor activation in the pituitary and hypothalamus has downstream consequences beyond growth hormone: in reported models, the earlier GHRPs also raise cortisol and prolactin, and GHRP-6 in particular carries a strong appetite signal — which is the ghrelin-like property, since ghrelin is the hunger hormone. Ipamorelin was introduced as the first compound in the class reported to produce the growth hormone response with minimal effect on the others. That profile is its whole research identity.
Why would a less selective compound still be useful?
Because sometimes the other effects are the subject. GHRP-6's appetite signal makes it a tool for studying ghrelin receptor involvement in feeding; a selective compound would be the wrong choice for that question. A compound is not better or worse in general, only for a purpose, and GHRP-6 in the catalogue is there for work where its full profile is wanted rather than avoided.
Reading the structure
The three sequences make a small case study in peptide design.
The aromatic core. A tryptophan or a naphthylalanine at the centre is common to all three. Naphthylalanine — a non-natural residue with a two-ring side chain — replaces tryptophan in GHRP-2 and ipamorelin, and the larger, more rigid group is associated with tighter receptor engagement.
The D residues. Each sits at a position a protease would otherwise cut. They are stability modifications first, and their effect on receptor binding is a secondary consequence that had to be checked.
The N-terminus. GHRP-6 starts with histidine; GHRP-2 with D-alanine; ipamorelin with 2-aminoisobutyric acid — the same residue that blocks DPP-4 in the incretins, doing a similar job here. Each choice changes both stability and the shape presented to the receptor, and the selectivity difference is thought to come largely from here.
Do they differ in half-life?
All three are short-lived by the standards of an acylated peptide — minutes to a low number of hours — because none carries an albumin-binding group or a size extension. The D residues and capped termini resist exopeptidases, which is what gets them from seconds to minutes; nothing gets them to days. That places them in the short-acting category by design, which suits work on pulsatile release and is the reason they are paired with a GHRH analogue rather than substituted for one.
Why is ipamorelin the one paired with GHRH analogues?
Because a selective ghrelin-receptor signal is the cleaner partner. The two receptor groups converge on the same release event, and combining them is the standard model for studying that convergence. If the ghrelin-side compound also drives cortisol and prolactin, those confound the readout; ipamorelin's profile leaves the combination interpretable. CJC-1295 with ipamorelin and tesamorelin with ipamorelin are that pairing at two durations, and which GHRH analogue sits on the other side is a separate decision about time.
Can these be compared in a simple receptor assay?
Affinity, yes; selectivity, no. A binding or calcium assay on cells expressing the ghrelin receptor will rank the three by how tightly they engage it, and that ranking is real and reproducible. It says nothing about cortisol, prolactin or appetite, because those responses arise in a system, not at the receptor. Selectivity is a property of the whole organism's response to receptor activation in different tissues, and it can only be measured there. A paper reporting ipamorelin as "more selective" on the basis of an in-vitro receptor assay has measured affinity and named it something else — the same category error as reading a receptor count as a potency ranking.
What should a methods section record for this group?
The exact compound and its sequence, since the three are close enough in name and structure to be confused; the lot and net peptide content; and, for any combination with a GHRH analogue, both components and their ratio. If selectivity is part of the claim, the readouts that establish it — not only the growth hormone response but the ones it is being selective against. The two secretagogue groups are already confused often enough in the literature without a methods section adding to it.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
